Differentiated thyroid tumors: Surgical indications

Giornale di Chirurgia

Volumn 34, Issue 5-6, 2013, Pages 153-157

  Lucchini, R ^a   Monacelli, M ^a   Santoprete, S ^a   Triola, R ^a   Conti, C ^a   Pecoriello, R ^a   Favoriti, P ^a   Di Patrizi, M S ^a   Barillaro, I ^a   Boccolini, A ^a   Avenia, S ^a   D'Ajello, M ^a   Sanguinetti, A ^a   Avenia, N ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Differentiated tumor; Surgery; Thyroid

Indexed keywords

ADULT; FEMALE; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; THYROID NEOPLASMS; THYROIDECTOMY; ARTICLE; THYROID TUMOR;

ADULT; FEMALE; HUMANS; MALE; MIDDLE AGED; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 84891642303     PISSN: 03919005     EISSN: 1971145X     Source Type: Journal    
DOI: 10.11138/gchir/2013.34.5.153     Document Type: Article

References (42)

1. Linee guida per la gestione dei pazienti affetti da noduli tiroidei e carcinoma della tiroide, Ottobre 2008. I quaderni, n 13. A cura della Direzione Regionale Sanità e Servizi Sociali della regione Umbria.
2. Shaha AR. Advances in the management of thyroid cancer. Int J Surgery 2005;3:213-220.
3. Besic N. Extent of thyroidectomy and lymphadenectomy in 254 patients with papillary thyroid microcarcinoma: a single-institution experience. Ann Surg Oncol 2009;16(4):920-8
4. Salter KD, Andersen PE, Cohen JI, Schuff KG, Lester L, Shindo ML, Sauer D, Gross ND. Central nodal metastases in papillary thyroid carcinoma based on tumor histologic type and focality. Arch Otolaryngol Head Neck Surg 2010;136(7):692-6.
5. Noguchi S, Yamashita H, Uchino S, Watanabe S. Papillary microcarcinoma. World J Surg 2008;32:747-753.
6. Arora N. Papillary thyroid carcinoma and microcarcinoma:is there a need to distinguish the two? Thyroid 2009 May;19(5):473-7.
7. Clark OH. Total thyroidectomy: the treatment of choice for patient with differentiated thyroid cancer. Ann Surg 1982;196:361-70.
8. Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, Brokhin M, Omry G, Fagin JA, Shaha A. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initioal risk estimates predicted by new American thyroid association staging system. Thyroid 2010;20:1341-50.
9. Avenia N, Cristofani R, Puma F, Fonsi GB, Scalercio V, Urbani M, Ricci E, Servoli A. Il trattamento chirurgico del cancro della tiroide: analisi di 207 casi trattati. Osp Ital Chir 1999;5;451-6.
10. Milan SA, Sosa JA, Roman SA. Chirurgia mini-invasiva per il cancro invasivo della tiroide. Min Chir 2010 Febbraio;65(1):39-43.
11. Ducic Y, Young L, McIntyre J. Approccio "multi-target" nel trattamento del cancro della tiroide. Min Chir 2010 Febbraio;65(1):59-69.
12. Zarebczan B, Chen H. Problematiche nella chirurgia del cancro della tiroide. Min Chir 2010;65(1):83-93.
13. McHenry CR, Phitayakorn R. Follicular adenoma and carcinoma of the thyroid gland. Oncologist 2011;16(5):585-93. Epub 2011 Apr 11.
14. Ahmadi N, Grewal, Davidson BJ. Patterns of Cervical Lymph Node Metastases in Primary and Recurrent Papillary Thyroid Cancer. J Oncol 2011;2011:735678. Epub 2011 Nov 17.
15. Kuru B, Topgul K. The 2009 Revised American Thyroid Association Guidelines for Thyroid Cancer: The Extent of Surgery for Thyroid Carcinoma Less Than One and One Half Centimeters or Low Risk Thyroid Carcinoma. Thyroid 2011 Dec 16.
16. Milas Z., Shin J., Milas M. New guidelines for the management of thyroid nodules and differentiated thyroid cancer. Minerva Endocrinologica 2011 March;36(1):53-70.
17. Falvo L, Catania A, D'Andrea V, Marzullo A, Giustiniani MC, De Antoni E. Prognostic importance of histologic vascular invasion in papillary thyroid carcinoma. Ann Surg 2005; 241:640-6.
18. Falvo L, Catania A, Sorrenti S, D'Andrea V, Berni A, De Stefano M, De Antoni E. Prognostic significance of the age factor in the thyroid cancer: statistical analysis. J Surg Oncol 2004;88:217-22.
19. Falvo L, D'Ercole C, Sorrenti S, D'Andrea V, Catania A, Berni A, Grilli P, De Antoni E. Papillary microcarcinoma of the thyroid gland: analysis of prognostic factors including histological subtype. Eur J Surg Suppl 2003 Jul;(588):28-32.
20. González-González A, Mate-Valdezate A, Parra-Arroyo A, Tenías Burillo JM. New guidelines for the management of thyroid nodules and differentiated thyroid cancer. Minerva Endocrinol 2011 Mar;36(1):7-12.
21. Baldini E, Sorrenti S, Catania A, Guaitoli E, Prinzi N, Mocini R, Nardi F, D'Armiento E, Bianchini M, Favoriti P, Di Matteo FM, Ruggieri M, De Antoni E, Ulisse S. Diagnostic utility of thyroglobulin measurement in the fine needle aspirates from cervical lymph nodes: a case report. G Chir 2012;33:387-91.
22. Baldini EP, Sorrenti S, Di Gioia C, De Vito C, Antonelli A, Gnessi L, Carbotta G, D'Armiento E, Miccoli P, De Antoni E, Ulisse S. Cervical lymph node metastases from thyroid cancer: does thyroglobulin and calcitonin measurement in fine needle aspirates improve the diagnostic value of cytology? BMC Clin Pathol;2013;13:7.
23. Brown RL, de Souza JA, Cohen EE. Thyroid cancer: burden of illness and management of disease. J Cancer 2011 Apr 4;2:193-9.
24. Moretti S, De Falco V, Tamburrino A, Barbi F, Tavano M, Avenia N, Santeusanio F, Santoro M, Macchiarulo A, Puxeddu E. Insights into the molecular function of the inactivating mutations of B-Raf involving the DFG motif. Biochim Biophys Acta 2009 Nov;1793(11):1634-45. Epub 2009 Sep 6.
25. Puxeddu E, Durante C, Avenia N, Filetti S, Russo D. Clinical implications of BRAF mutation in thyroid carcinoma. Trends Endocrinol Metab 2008 May-Jun;19(4):138-45. Epub 2008 Mar 11.
26. Hay ID, Bergastralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one istitution during 1940 through 1989. Surgery 1993;114(6):1050-7.
27. Mazzaferri EL, Young RL. Papillary thyroid carcinoma: 10 year follow up report of the impact of terapy in 576 patients. Am J Med 1981;70(3):511-8.
28. Cirocchi R, Trastulli S, Sanguinetti A, Cattorini L, Covarelli P, Giannotti D, Di Rocco G, Rondelli F, Barberini F, Boselli C, Santoro A, Gullà N, Redler A, Avenia N. Recurrent differentiated thyroid cancer: to cut or burn. World J Surg Oncol 2011 Aug 12;9:89.
29. Moretti S, De Falco V, Tamburrino A, Barbi F, Tavano M, Avenia N, Santeusanio F, Santoro M, Macchiarulo A, Puxeddu E. Insights into the molecular function of the inactivating mutations of B-Raf involving the DFG motif. Biochim Biophys Acta 2009 Nov;1793(11):1634-45.
30. Rosato L, Miccoli P, Pinchera A, Lombardi G, Romano M, Avenia N, Bastagli A, Bellantone R, De Palma M, De Toma G, Gasparri G, Lampugnani R, Marini PL, Nasi PG, Pellizzo MR, Pezzullo L, Piccoli M, Testini M. Diagnostic, therapeutic and healthcare management protocols in thyroid surgery. 2nd Consensus Conference (U.E.C. CLUB)]. G Chir 2009 Mar;30(3):73-86.
31. Lucchini R, Puxeddu E, Calzolari F, Burzelli F, Monacelli M, D'Ajello F, Macaluso R, Giammartino C, Ragusa M, De Feo P, Cavaliere A, Avenia N. Recurrences of thyroid well differentiated cancer: ultrasonography-guided surgical treatment. Minerva Chir 2008 Aug 63(4):257-60.
32. Puxeddu E, Durante C, Avenia N, Filetti S, Russo D. Clinical implications of BRAF mutation in thyroid carcinoma. Trends Endocrinol Metab 2008 May-Jun;19(4):138-45.
33. Puxeddu E, Susta F, Orvietani PL, Chiasserini D, Barbi F, Moretti S, Cavaliere A, Santeusanio F, Avenia N, Binaglia L. Identification of differentially expressed proteins in papillary thyroid carcinomas with V600E mutation of BRAF. Proteomics Clin Appl 2007 Jul;1(7):672-80.
34. Durante C, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R, Barbi F, Avenia N, Scipioni A, Verrienti A, Tosi E, Cavaliere A, Gulino A, Filetti S, Russo D. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab 2007 Jul;92(7):2840-3. Epub 2007 May 8.
35. Fugazzola L, Puxeddu E, Avenia N, Romei C, Cirello V, Cavaliere A, Faviana P, Mannavola D, Moretti S, Rossi S, Sculli M, Bottici V, Beck-Peccoz P, Pacini F, Pinchera A, Santeusanio F, Elisei R. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer 2006 Jun;13(2):455-64.
36. Moretti S, Macchiarulo A, De Falco V, Avenia N, Barbi F, Carta C, Cavaliere A, Melillo RM, Passeri L, Santeusanio F, Tartaglia M, Santoro M, Puxeddu E. Biochemical and molecular characterization of the novel BRAF(V599Ins) mutation detected in a classic papillary thyroid carcinoma. Oncogene 2006 Jul 13;25(30):4235-40.
37. Carta C, Moretti S, Passeri L, Barbi F, Avenia N, Cavaliere A, Monacelli M, Macchiarulo A, Santeusanio F, Tartaglia M, Puxeddu E. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)). Clin Endocrinol (Oxf) 2006 Jan;64(1):105-9.
38. Puxeddu E, Moretti S, Elisei R, Romei C, Pascucci R, Martinelli M, Marino C, Avenia N, Rossi ED, Fadda G, Cavaliere A, Ribacchi R, Falorni A, Pontecorvi A, Pacini F, Pinchera A, Santeusanio F. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab 2004 May;89(5):2414-20.
39. Rosato L, Avenia N, Bernante P, De Palma M, Gulino G, Nasi PG, Pelizzo MR, Pezzullo L. Complications of thyroid surgery: analysis of a multicentric study on 14,934 patients operated on in Italy over 5 years. World J Surg 2004 Mar;28(3):271-6.
40. Puxeddu E, Moretti S, Giannico A, Martinelli M, Marino C, Avenia N, Cristofani R, Farabi R, Reboldi G, Ribacchi R, Pontecorvi A, Santeusanio F. Ret/PTC activation does not influence clinical and pathological features of adult papillary thyroid carcinomas. Eur J Endocrinol 2003 May;148(5):505-13.
41. Ulisse S, Baldini E, Sorrenti S, Barollo S, Prinzi N, Catania A, Nesca A, Gnessi L, Pelizzo MR, Mian C, De Vito C, Calvanese A, Palermo S, Persechino S, De Antoni E, D'Armiento M. In papillary thyroid carcinoma BRAFV600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval. Clin Endocrinol 2012;77:780-6.
42. Ulisse S, Baldini E, Sorrenti S, Barollo S, Gnessi L, Catania A, Pellizzo MR, Nardi F, Mian C, De Antoni E, D'Armiento M, Frati L. High expression of the urokinase plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma. J Clin Endocrinol Metab 2011;96:504-8.